Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Int Med Res ; 47(6): 2533-2544, 2019 Jun.
Article in English | MEDLINE | ID: mdl-31039653

ABSTRACT

OBJECTIVE: To evaluate the ability of two scoring systems (CHA2DS2-VASc score and CHA2DS2-VASc+hyperlipidaemia+smoking [CHA2DS2-VASc-HS score]) to predict in-stent restenosis (ISR) among patients undergoing drug-eluting stent (DES) implantation. METHODS: This retrospective study enrolled patients who underwent coronary angiography to assess coronary artery disease severity secondary to a diagnosis of stable angina or acute coronary syndrome that subsequently underwent DES implantations. Demographic, clinical, angiographic and biochemical parameters were compared between those patients that experienced ISR and those that did not during the study follow-up period. Univariate and multivariate logistic regression analyses were used to evaluate associations between the baseline parameters, the two scoring systems and ISR risk. RESULTS: A total of 358 patients (non-ISR group n = 316; ISR group n = 42) participated in the study. Compared with the non-ISR group, more patients in the ISR group had diabetes mellitus and received stents with smaller diameters but longer lengths. There were no significant differences with regard the predictive ability for ISR of either the CHA2DS2-Vasc or the CHA2DS2-Vasc-HS scores. Multivariate logistic regression analyses demonstrated that stent diameter, follow-up duration and glycosylated haemoglobin were independent risk factors for ISR. CONCLUSIONS: The CHA2DS2-Vasc and CHA2DS2-Vasc-HS scores did not predict ISR in patients after coronary DES placement.


Subject(s)
Coronary Artery Disease/surgery , Coronary Restenosis/diagnosis , Models, Statistical , Percutaneous Coronary Intervention/adverse effects , Risk Assessment/methods , Stents/adverse effects , Aged , Coronary Restenosis/etiology , Female , Follow-Up Studies , Humans , Logistic Models , Male , Middle Aged , Prognosis , ROC Curve , Retrospective Studies
2.
J Int Med Res ; 47(6): 2709-2715, 2019 Jun.
Article in English | MEDLINE | ID: mdl-31014143

ABSTRACT

During the past century, the incidence of myocardial infarction has markedly increased worldwide. Percutaneous coronary intervention with stent implantation is often considered as the first-choice treatment, especially in emergency cases. Current guidelines recommend delayed elective noncardiac surgery for such vulnerable patients. However, few suggestions are available regarding the exact treatment strategy for patients who have already undergone percutaneous coronary intervention but suddenly need emergent noncardiac surgery for an unrelated reason. We herein present a case involving a patient with acute myocardial infarction who had undergone implantation of a drug-eluting stent and developed an ileal perforation due to fish bone ingestion 3 days postoperatively. After carefully balancing the risks of stent thrombosis and uncontrollable bleeding, dual antiplatelet therapy and low-molecular-weight heparin were given with close monitoring. Emergency laparotomy and partial small bowel resection surgery were then performed, after which the patient eventually recovered. This case indicates a possible management strategy for patients with acute myocardial infarction complicated by emergency noncardiac surgery.


Subject(s)
Drug-Eluting Stents , Foreign Bodies/complications , Gastrointestinal Hemorrhage/etiology , Ileal Diseases/etiology , Intestinal Perforation/etiology , Myocardial Infarction/therapy , Seafood/adverse effects , Aged , Animals , Female , Fishes , Foreign Bodies/surgery , Gastrointestinal Hemorrhage/pathology , Gastrointestinal Hemorrhage/surgery , Humans , Ileal Diseases/pathology , Ileal Diseases/surgery , Intestinal Perforation/pathology , Intestinal Perforation/surgery , Myocardial Infarction/complications , Percutaneous Coronary Intervention , Prognosis
3.
Cell Physiol Biochem ; 38(6): 2311-22, 2016.
Article in English | MEDLINE | ID: mdl-27197836

ABSTRACT

BACKGROUND/AIMS: Amiodarone, a thyroid hormone-like molecule, can induce dyslipidemia and thyroid dysfunction. However, the effects of dronedarone on lipid metabolism and of both dronedarone and amiodarone on thyroid function and lipid metabolism remain unknown. METHODS: Fifty male Sprague-Dawley rats were randomly divided into 5 groups (10 in each group): normal control (NC), amiodarone-treated (AMT), dronedarone-treated (DRT), rats treated with amiodarone combined with polyene phosphatidylcholine (AC), and rats treated with dronedarone combined with polyene phosphatidylcholine (DC). Rats were given amiodarone (120 mg/kg/d), dronedarone (120 mg/kg/d), and polyene phosphatidylcholine (200 mg/kg/d) for 13 weeks. At the end of weeks 4, 8, 12, and 13, plasma-free triiodothyronine (FT3), free thyroxine (FT4), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c) were determined. At the end of this protocol, rats were sacrificed and the thyroid glands were isolated, weighed, and examined histopathologically. The protein expression of Bcl-2 was measured by immunochemical staining. The mRNA expression of thyroglobulin (Tg), type-1 deiodinase (D1), and thyroid peroxidase (TPO) were detected by polymerase chain reaction (PCR). RESULTS: Compared with the NC group, FT3 and FT4 levels in the DRT and DC groups significantly increased at week 4 but declined thereafter. The AMT and AC groups had lower FT3 levels but comparable FT4 levels. The levels of TG, LDL-c, and HDL-c in the NC group were lower than those in the other groups whereas the LDL-c/HDL-c ratio was lowest in the AMT group. Bcl-2 expression significantly increased in the DRT group. The mRNA expression of Tg increased whereas the mRNA expression of D1 decreased. Dronedarone induced hyperthyroidism at the early stage and hypothyroidism at the late stage whereas amiodarone only caused hypothyroidism. CONCLUSION: Both dronedarone and amiodarone can induce dyslipidemia and increase the levels of TC, LDL-c, and HDL-c, and these effects may be associated with thyroid dysfunction.


Subject(s)
Amiodarone/analogs & derivatives , Amiodarone/adverse effects , Anti-Arrhythmia Agents/adverse effects , Dyslipidemias/chemically induced , Thyroid Gland/drug effects , Thyroid Gland/pathology , Vasodilator Agents/adverse effects , Animals , Dronedarone , Dyslipidemias/blood , Dyslipidemias/metabolism , Dyslipidemias/pathology , Lipid Metabolism/drug effects , Lipids/blood , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Proto-Oncogene Proteins c-bcl-2/analysis , Rats, Sprague-Dawley , Thyroid Gland/metabolism , Thyroxine/blood , Thyroxine/metabolism , Triiodothyronine/blood , Triiodothyronine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...